Physician profile
Robert Redner
NPI 1851367684
$4,142.40
in general payments reported to CMS, 2019-2025
17 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $222 · 2021: $43.36 · 2022: $135 · 2023: $106 · 2024: $1,244 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Travel and Lodging: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.16 |
| Travel and Lodging | $432.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,111.87 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $697.51 | 2019-2025 | Calquence |
| Abbvie INC. | $568.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.93 | 2019-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $284.28 | 2025 | Vanflyta, Injectafer |
| Amgen INC. | $233.49 | 2020-2024 | Nplate |
| Astellas Pharma US INC | $200.70 | 2019 | |
| Syndax Pharmaceuticals, INC. | $127.00 | 2025 | Revuforj |
| Geron Corporation | $122.66 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $109.59 | 2019 | |
| Sobi, INC | $105.82 | 2023 | |
| Adc Therapeutics America, INC. | $102.56 | 2025 | |
| Incyte Corporation | $94.07 | 2025 | Niktimvo |
| Servier Pharmaceuticals LLC | $43.36 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Redner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.